Small molecules: an overview of emerging therapeutic options in the treatment of psoriasis.

Small molecules: an overview of emerging therapeutic options in the treatment of psoriasis. Skin Therapy Lett. 2013 Dec;18(7):1-4 Authors: Gooderham M Abstract Psoriasis is a chronic condition which requires ongoing management with therapies that have demonstrated favorable safety and efficacy profiles in long-term use. While biologics changed the way psoriasis is treated by providing effective targeted therapy, they are not without limitations. However, small molecules are emerging therapeutic options for the treatment of psoriasis. Several oral and topical small molecules, spanning different therapeutic classes, are proving to be promising treatment options in psoriasis. While studies to date have yielded positive results, further investigation of these agents are warranted for both safety and efficacy. PMID: 24305752 [PubMed - in process]
Source: Skin Therapy Letter - Category: Dermatology Authors: Tags: Skin Therapy Lett Source Type: research

Related Links:

In this study, we re port a library of 73 novel psoralens, the largest collection of its kind. When screened for the ability to induce cell death, we identified two derivatives even more cytotoxic than 4’‐aminomethyl‐4,5’,8‐trimethylpsoralen (AMT), one of the most potent psoralens identified to date. Using MAL DI‐TOF MS, we studied the DNA adduct formation of a subset of novel psoralens and found that in most cases enhanced DNA binding correlated well with cytotoxicity. Generally, our most active derivatives contain positively charged substituents, which we believe increase DNA affinity and enhance psor...
Source: Photochemistry and Photobiology - Category: Science Authors: Tags: RESEARCH ARTICLE Source Type: research
Conclusion: Palmoplantar pustulosis appears to be a distinct entity from psoriasis. Routine thyroid functions test could be analyzed, but patch testing is not required in patients with palmoplantar pustulosis. Also, patients with palmoplantar pustulosis must be evaluated for musculoskeletal symptoms and signs.
Source: Anais Brasileiros de Dermatologia - Category: Dermatology Source Type: research
Conclusion: This is the first Argentine study that evaluated the costs of moderate/severe psoriasis by taking into consideration the direct medical costs of the disease.
Source: Anais Brasileiros de Dermatologia - Category: Dermatology Source Type: research
Conclusion: CYP2J2 50G>T (rs890293) polymorphism was associated with an increased risk for PsV in the Turkish population.
Source: Anais Brasileiros de Dermatologia - Category: Dermatology Source Type: research
The objective of this retrospective study is to assess the C-reactive protein, monocyte-to-high-density-lipoprotein ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio as inflammatory markers in patients with psoriasis and to search for a relationship between these parameters and psoriasis severity, as defined by the psoriasis area and severity index. Methods: There were 94 patients with psoriasis and 118 healthy controls enrolled in the study. The C-reactive protein, monocyte-to-high-density-lipoprotein ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, a...
Source: Anais Brasileiros de Dermatologia - Category: Dermatology Source Type: research
Abstract White fibrous papulosis of the neck is a rare entity, with fewer than 50 cases described. It is a benign pathology whose main interest lies in its broad differential diagnosis, especially with pseudoxanthoma elasticum. The authors report the case of a 77-year-old woman with multiple yellow-white monomorphic papules on the posterior cervical region, with years of evolution. Cutaneous biopsy revealed a nodular area in the superficial and middle reticular dermis, with slight thickening of the collagen fibers and focally enlarged elastic fibers, aspects highlighted in the Verhoeff staining that additionally showed abs...
Source: Anais Brasileiros de Dermatologia - Category: Dermatology Source Type: research
Taltz is the first and only IL-17A antagonist approved to treat this population INDIANAPOLIS, March 30, 2020 -- (Healthcare Sales &Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has ... Biopharmaceuticals, Dermatology, FDA Eli Lilly, Taltz, ixekizumab, plaque psoriasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
INDIANAPOLIS, March 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz (ixekizumab) injection, 80 mg/mL...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
This study will provide high-level clinical evidence for internal and external TCM treatment optimization and will contribute to establishing norms for the integration of Chinese and western Medicines.Trial registrationClinicalTrials.gov,NCT03941431. Registered on 8 May 2019.
Source: Trials - Category: Research Source Type: clinical trials
CONCLUSIONS: Psoriasis is associated with a small increase in the risk of serious infection. Further research is needed to understand how psoriasis predisposes to a higher risk of infection. PMID: 32222069 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
More News: Dermatology | Psoriasis | Skin | Study